DNM2 and breast cancer: In clinic, ERα was used as another key target for endocrine therapy in the ERα‐positive breast cancers, which accounted for ~70% of all breast cancers.[44, 45] As a transcriptional promoter of vinculin that was a cytoskeletal protein associated with linkage of transmembrane integrins to intracellular actin cytoskeletons, ERα expressed in the MCF‐7 cells might be downregulated by fulvestrant (Figure S10A,B, Supporting Information), which could in turn promote focal adhesion turnover and thus increase their invasive and metastatic ability,[46] as demonstrated by our transwell assay (Figure6A).